Literature DB >> 17308098

Tumor-suppressive effect of retinoid receptor-induced gene-1 (RRIG1) in esophageal cancer.

Jie Huang1, Zheng D Liang, Tsung-Teh Wu, Ashraful Hoque, Hongli Chen, Yan Jiang, Hongfu Zhang, Xiao-Chun Xu.   

Abstract

We previously showed that induction of retinoid receptor-induced gene-1 (RRIG1) expression inhibited RhoA activation and tumor cell colony formation, invasion, and proliferation, and these effects are associated with the suppression of extracellular signal-regulated protein kinases 1 and 2 phosphorylation and cyclooxygenase-2 expression. To further elucidate its role in tumor cell growth, gene expression, and tumorigenesis, we determined RRIG1 expression in breast and esophageal tissue specimens and then stably transfected RRIG1 into a TE-8 esophageal squamous cell carcinoma (SCC) cell line. We found that RRIG1 was expressed in normal mammary glands (10 of 10) but not all ductal carcinoma in situ [11 of 19 (57.9%), P = 0.018] and invasive cancer [14 of 30 (46.7%), P = 0.0023] tissues. Similarly, RRIG1 was expressed in normal esophageal epithelium (22 of 22) but not all dysplastic [6 of 43 (14%), P = 0.0001] and SCC [50 of 122 (41%), P = 0.0001] tissues. Furthermore, RRIG1 expression correlated positively with tumor differentiation but inversely with lymph node metastasis of esophageal SCC. Finally, the stable transfection of RRIG1 inhibited esophageal SCC cell growth and the expression of extracellular signal-regulated protein kinases 1 and 2 and cell cycle-related genes (e.g., cyclin D1, phosphorylated Rb, and E2F). RRIG1-transfected sublines also inhibited tumor development in nude mice. The results of this study indicate that RRIG1 plays a role in suppressing tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17308098     DOI: 10.1158/0008-5472.CAN-06-2472

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  7 in total

Review 1.  Tumor-suppressive activity of retinoic acid receptor-beta in cancer.

Authors:  Xiao-Chun Xu
Journal:  Cancer Lett       Date:  2006-12-22       Impact factor: 8.679

2.  Suppression of esophageal cancer cell growth using curcumin, (-)-epigallocatechin-3-gallate and lovastatin.

Authors:  Fei Ye; Gui-Hong Zhang; Bao-Xiang Guan; Xiao-Chun Xu
Journal:  World J Gastroenterol       Date:  2012-01-14       Impact factor: 5.742

3.  Tumor-suppressor activity of RRIG1 in breast cancer.

Authors:  Guihong Zhang; Abenaa Brewster; Baoxiang Guan; Zhen Fan; Powel H Brown; Xiao-Chun Xu
Journal:  BMC Cancer       Date:  2011-01-25       Impact factor: 4.430

4.  Inhibition of farnesoid X receptor controls esophageal cancer cell growth in vitro and in nude mouse xenografts.

Authors:  Baoxiang Guan; Hao Li; Zhengduo Yang; Ashraful Hoque; Xiaochun Xu
Journal:  Cancer       Date:  2012-12-20       Impact factor: 6.860

5.  Lasiodin inhibits proliferation of human nasopharyngeal carcinoma cells by simultaneous modulation of the Apaf-1/caspase, AKT/MAPK and COX-2/NF-κB signaling pathways.

Authors:  Lianzhu Lin; Wuguo Deng; Yun Tian; Wangbing Chen; Jingshu Wang; Lingyi Fu; Dingbo Shi; Mouming Zhao; Wei Luo
Journal:  PLoS One       Date:  2014-05-20       Impact factor: 3.240

6.  Effusanin E suppresses nasopharyngeal carcinoma cell growth by inhibiting NF-κB and COX-2 signaling.

Authors:  Mingzhu Zhuang; Mouming Zhao; Huijuan Qiu; Dingbo Shi; Jingshu Wang; Yun Tian; Lianzhu Lin; Wuguo Deng
Journal:  PLoS One       Date:  2014-10-21       Impact factor: 3.240

7.  Triptolide Combined with Radiotherapy for the Treatment of Nasopharyngeal Carcinoma via NF-κB-Related Mechanism.

Authors:  Weiying Zhang; Min Kang; Tingting Zhang; Bo Li; Xueyin Liao; Rensheng Wang
Journal:  Int J Mol Sci       Date:  2016-12-19       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.